Elevance Health

ELV

Market cap $70.6B

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. C.

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health Foundation has awarded 22 new grants totaling more than $2.3 million to support food as medicine programs across the country. These grants will help nonprofit organizations improve access to nutritious food and advance clinical outcomes for individuals and families experiencing food and nutrition insecurity, particularly those living with diet-related chronic conditions. This latest round of funding is part of the Foundation's five-year, $150 milli.

Investors need to pay close attention to ELV stock based on the movements in the options market lately.

My Top 15 dividend growth stocks for February 2026 offer a 1.52% yield, 15.48% five-year dividend growth and are about 27% undervalued.

Elevance Health Inc (NYSE:ELV) stock yesterday enjoyed its biggest single-day percentage gain since May 2024 after reporting $547 million in profits, but it wasn't enough to erase its worst day since March 2020 in the previous session, after the Centers for Medicare & Medicaid Services proposed to raise Medicare Advantage payment rates by only 0.09% in 2027.

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Elevance Health, Inc. (ELV) Q4 2025 Earnings Call Transcript

Elevance Health, Inc. faces persistent margin and volume pressures, with Q4 operating revenue down 55% YoY and weak 2026 guidance. ELV's benefit expense ratio remains elevated at 90%, with medical inflation and higher utilization driving cost pressures and reduced profitability. Guidance for 2026 anticipates revenue and EPS declines, with adjusted EPS expected to drop 16% and investment income down 15%.

Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elevance Health Inc. (NYSE: ELV) shares fell after the health insurer reported mixed fourth-quarter 2025 earnings and bleak fiscal 2026 guidance. The stock has recovered most of its loss from the premarket session